We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSinclair Pharma Regulatory News (SPH)

  • There is currently no data for SPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

17 Oct 2018 08:06

RNS Number : 3159E
Sinclair Pharma PLC
17 October 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Sinclair Pharma PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Weiss Asset Management LP

City and country of registered office (if applicable)

Wilmington, Delaware, USA

4. Full name of shareholder(s) (if different from 3.)v

Name

Brookdale International Partners, L.P., Brookdale Global Opportunity Fund

City and country of registered office (if applicable)

Brookdale International Partners, L.P.: New York, NY, USA

Brookdale Global Opportunity Fund: Grand Cayman, Cayman Islands

5. Date on which the threshold was crossed or reachedvi:

Oct-16-2018

6. Date on which issuer notified (DD/MM/YYYY):

Oct-16-2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

0.0 %

12.11 %

12.11 %

503,768,952

Position of previous notification (if

applicable)

0.0 %

5.20 %

5.20 %

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

SUBTOTAL 8. A

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

CFD

N/A

N/A

Cash Settlement

60,997,322

12.11 %

SUBTOTAL 8.B.2

60,997,322

12.11 %

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Weiss Asset Management LP

Brookdale International Partners, L.P.

8.11%

8.11%

Weiss Asset Management LP

Brookdale Global Opportunity Fund

Below 5.0%

Below 5.0%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Weiss Asset Management LP is the Investment Manager to Brookdale Global Opportunity Fund and Brookdale International Partners, L.P.

 

Place of completion

Boston, USA

Date of completion

Oct-16-2018

 

Annex: Notification of major holdings (to be filed with the FCA only)

A: Identity of the person subject to the notification obligation

Full name (including legal form for legal entities)

Weiss Asset Management LP

Contact address (registered office for legal entities)

222 Berkeley St., 16th Floor,

Boston, MA 02116, USA

E-Mail

compliance@weissasset.com

Phone number / Fax number

+1-617-778-7780

Other useful information

(at least legal representative for legal persons)

Attn: Georgiy Nikitin

B: Identity of the notifier, if applicable

Full name

Contact address

E-Mail

Phone number / Fax number

Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

 

 

Please send the completed form together with this annex to the FCA at the following email

address: Majorshareholdings@fca.org.uk. Please send in Microsoft Word format if possible.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLMRBRTMBMBMJP
Date   Source Headline
5th Nov 20181:43 pmRNSForm 8.3 - Sinclair Pharma PLC
5th Nov 20187:30 amRNSSuspension - Sinclair Pharma Plc
5th Nov 20187:00 amRNSScheme of Arrangement becomes Effective
2nd Nov 201812:55 pmRNSPUBLIC DEALING DISCLOSURE
2nd Nov 201812:40 pmRNSPUBLIC DEALING DISCLOSURE
2nd Nov 201812:36 pmRNSRule 2.9 Announcement
2nd Nov 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
2nd Nov 20187:44 amRNSForm 8.3 - Sinclair Pharma PLC
1st Nov 20183:45 pmRNSAdditional Listing
1st Nov 20183:08 pmRNSForm 8.3 - Sinclair Pharma plc
1st Nov 201812:43 pmRNSCourt sanction of the scheme of arrangement
31st Oct 20182:25 pmRNSForm 8.3 - Sinclair Pharma plc
30th Oct 20182:29 pmRNSForm 8.3 - Sinclair Pharma plc
29th Oct 20185:30 pmRNSSinclair Pharma
29th Oct 20182:44 pmRNSForm 8.3 - Sinclair Pharma plc
29th Oct 20189:23 amRNSForm 8.3 - Sinclair Pharma Plc
29th Oct 20188:24 amRNSForm 8.3 - Sinclair Pharma PLC
26th Oct 20188:33 amRNSForm 8.3 - Sinclair Pharma PLC
25th Oct 20189:41 amRNSForm 8.3 - Sinclair Pharma PLC
24th Oct 20183:08 pmRNSForm 8.3 - SINCLAIR Pharma PLC
24th Oct 20182:39 pmRNSResults of Court Meeting and General Meeting
23rd Oct 20183:35 pmRNSForm 8.3 - Sinclair Pharma plc
23rd Oct 20182:23 pmRNSHolding(s) in Company
23rd Oct 201812:37 pmGNWMan Group PLC : Form 8.3 - Sinclair Pharma plc
22nd Oct 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
19th Oct 20183:01 pmRNSForm 8.3 - SINCLAIR PHARMA PLC
19th Oct 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
19th Oct 201810:37 amRNSHolding(s) in Company
19th Oct 201810:35 amRNSHolding(s) in Company
18th Oct 20183:20 pmBUSForm 8.3 - Sinclair Pharma PLC
18th Oct 20183:15 pmRNSForm 8.3 - Sinclair Pharma plc
18th Oct 20182:59 pmBUSForm 8.3 - Sinclair Pharma plc
18th Oct 201812:00 pmRNSForm 8.5 (EPT/RI) - Sinclair Pharma Plc
18th Oct 201811:58 amRNSForm 8.3 - Sinclair Pharma Plc
18th Oct 201811:42 amGNWMan Group PLC : Form 8.3 - Sinclair Pharma plc
18th Oct 201810:44 amRNSForm 8.3 - Sinclair Pharma Plc
18th Oct 20189:40 amRNSForm 8.3 - [LMR Partners/Sinclair Pharma]
18th Oct 20187:00 amRNSDisclosure under Rule 2.10(c)
17th Oct 20184:49 pmRNSHolding(s) in Company
17th Oct 20184:46 pmRNSHolding(s) in Company
17th Oct 20183:30 pmRNSForm 8.3 - SPH LN
17th Oct 20183:19 pmRNSForm 8.3 - Sinclair Pharma plc
17th Oct 20183:15 pmRNSForm 8.3 - Sinclair Pharma plc
17th Oct 20183:11 pmRNSForm 8.3 - Sinclair Pharma PLC
17th Oct 20183:11 pmBUSForm 8.3 - Sinclair Pharma plc
17th Oct 20182:38 pmRNSForm 8.3 - Sinclair Pharma Plc
17th Oct 201812:30 pmRNSForm 8.3 - Sinclair Pharma plc
17th Oct 201812:29 pmGNWMan Group PLC : Form 8.3 - Sinclair Pharma plc
17th Oct 201812:20 pmRNSForm 8.3 - Sinclair Pharma Plc
17th Oct 20188:06 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.